MA38847B2 - Formulation médicamenteuse à libération retardée - Google Patents

Formulation médicamenteuse à libération retardée

Info

Publication number
MA38847B2
MA38847B2 MA38847A MA38847A MA38847B2 MA 38847 B2 MA38847 B2 MA 38847B2 MA 38847 A MA38847 A MA 38847A MA 38847 A MA38847 A MA 38847A MA 38847 B2 MA38847 B2 MA 38847B2
Authority
MA
Morocco
Prior art keywords
polymeric substance
soluble polymeric
delayed
release
inner layer
Prior art date
Application number
MA38847A
Other languages
English (en)
Other versions
MA38847A1 (fr
Inventor
González Roberto Carlos Bravo
Thomas Buser
Felipe José Oliveira Varum
Abdul Waseh Basit
Ana Cristina Freire
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MA38847A1 publication Critical patent/MA38847A1/fr
Publication of MA38847B2 publication Critical patent/MA38847B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dans une formulation à libération retardée comprenant un noyau contenant un médicament et un enrobage à libération retardée pour assurer la libération intestinale, la libération du médicament dans le côlon est accélérée par l'inclusion d'une couche isolante entre le noyau et l'enrobage à libération retardée. L'enrobage à libération retardée comprend une couche interne et une couche externe. La couche externe comprend une substance polymère soluble en fonction du ph dont le seuil de ph avoisine ph 5 ou plus. La couche interne comprend une substance polymère soluble qui est soluble dans le liquide intestinal ou le liquide gastro-intestinal, ladite substance polymère soluble étant choisie dans le groupe constitué d'un polymère d'acide polycarboxylique qui est au moins partiellement neutralisé, et d'un polymère non ionique, à condition que, lorsque ladite substance polymère soluble est un polymère non ionique, ladite couche interne comprenne au moins un additif choisi parmi un agent tampon et une base.
MA38847A 2013-10-29 2013-10-29 Formulation médicamenteuse à libération retardée MA38847B2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/072648 WO2015062640A1 (fr) 2013-10-29 2013-10-29 Formulation médicamenteuse à libération retardée

Publications (2)

Publication Number Publication Date
MA38847A1 MA38847A1 (fr) 2017-08-31
MA38847B2 true MA38847B2 (fr) 2021-02-26

Family

ID=49515360

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38847A MA38847B2 (fr) 2013-10-29 2013-10-29 Formulation médicamenteuse à libération retardée

Country Status (25)

Country Link
US (1) US10799515B2 (fr)
EP (2) EP3542791A1 (fr)
JP (1) JP6273356B2 (fr)
KR (2) KR102237356B1 (fr)
CN (2) CN110279669B (fr)
AU (2) AU2013404367B2 (fr)
BR (2) BR112016004863B1 (fr)
CA (1) CA2923063C (fr)
CR (1) CR20160192A (fr)
CU (1) CU20160055A7 (fr)
EA (1) EA032504B1 (fr)
HK (1) HK1222547A1 (fr)
IL (2) IL244260B (fr)
MA (1) MA38847B2 (fr)
MX (1) MX2016001840A (fr)
MY (1) MY189394A (fr)
NZ (2) NZ717159A (fr)
PH (1) PH12016500307A1 (fr)
SA (2) SA114360006B1 (fr)
SG (1) SG11201600501UA (fr)
TN (1) TN2016000119A1 (fr)
TW (3) TWI736031B (fr)
UA (1) UA117260C2 (fr)
WO (1) WO2015062640A1 (fr)
ZA (1) ZA201600630B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2659881B1 (fr) 2012-04-30 2017-11-29 Tillotts Pharma Ag Formulation de médicament à libération retardée
KR102279993B1 (ko) 2015-09-23 2021-07-21 엑스더블유파마 리미티드 감마-하이드록시부티르산의 전구체 및 이의 조성물 및 용도
EP3162362A1 (fr) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Comprimé optimisé a une haute dose contenant de la mesalazine
EP3257501A1 (fr) 2016-06-14 2017-12-20 Tillotts Pharma AG Forme galénique unitaire multiple comprenant un noyau avec différentes unités de coeur recouvertes par un matériau muco-adhésif et un revêtement noyau gastro-résistant
CA3085223A1 (fr) * 2017-12-21 2019-06-27 Pepsico, Inc. Capsule de boisson ephemere a plusieurs ingredients pour preparer une boisson
EP3662898A1 (fr) 2018-12-07 2020-06-10 Tillotts Pharma AG Formulation solide comprenant de la mésalamine
EP3662902A1 (fr) * 2018-12-07 2020-06-10 Tillotts Pharma AG Formulation pour la liberation de médicaments dans le côlon
EP3662900A1 (fr) * 2018-12-07 2020-06-10 Tillotts Pharma AG Formulation d'administration de médicament colonique
EP3662895A1 (fr) 2018-12-07 2020-06-10 Tillotts Pharma AG Procédé de fabrication de noyaux de comprimés réduisant le 5-asa sans sucre
EP3662901A1 (fr) * 2018-12-07 2020-06-10 Tillotts Pharma AG Formulation de medicaments a liberation ranlentie avec une couche exterieure comprenant un polymere degradable par des enzymes, sa composition et son processus de production
IL293648A (en) * 2019-12-11 2022-08-01 Evonik Operations Gmbh Dosage form for use in the treatment or prevention of disease

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) * 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CA2236605A1 (fr) 1997-05-09 1998-11-09 Yves Duccini Agents anti-tartre
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ATE238797T1 (de) 1999-12-16 2003-05-15 Medinfar Produtos Farmaceutico Piroxicam enthaltende gastrointestinale zubereitung aus merheren einheiten bestehend
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780A (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CN1293867C (zh) * 2001-05-25 2007-01-10 爱诗爱诗制药株式会社 药物复合制剂
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1560597A4 (fr) 2002-10-29 2007-06-27 Pharmacia Corp Genes exprimes de maniere differenciee impliques dans le cancer, polypeptides codes par ces genes, et methodes d'utilisation des genes
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (fr) 2002-12-24 2004-07-15 Lupin Limited Composition de fluoxetine a enrobage enterique
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1904039A2 (fr) 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Formulation galenique a liberation commandee de duloxetine
DE102005032806A1 (de) * 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
US20090175935A1 (en) 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
WO2008117814A1 (fr) 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. Préparation orale pharmaceutique destinée à une distribution spécifique pour le colon
SI2152250T1 (sl) 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
ES2856959T3 (es) 2009-06-15 2021-09-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para el tratamiento del ictus en un sujeto en terapia simultánea con estatina
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
JP5827952B2 (ja) 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
EP2384746A3 (fr) * 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions de comprimé oral de dexlansoprazole à libération duale
WO2012075015A2 (fr) 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques orales de métronidazole
AU2012305915B2 (en) 2011-09-07 2017-09-07 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal
CN102319218B (zh) * 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
EP2659881B1 (fr) 2012-04-30 2017-11-29 Tillotts Pharma Ag Formulation de médicament à libération retardée
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool

Also Published As

Publication number Publication date
TW202011945A (zh) 2020-04-01
MY189394A (en) 2022-02-09
MA38847A1 (fr) 2017-08-31
JP2016535030A (ja) 2016-11-10
KR20160077040A (ko) 2016-07-01
WO2015062640A1 (fr) 2015-05-07
BR122020013726B1 (pt) 2022-11-01
TWI680774B (zh) 2020-01-01
IL244260A0 (en) 2016-04-21
AU2013404367A1 (en) 2016-02-18
US20160250232A1 (en) 2016-09-01
AU2020201365A1 (en) 2020-03-12
MX2016001840A (es) 2016-08-11
HK1222547A1 (zh) 2017-07-07
BR112016004863A8 (pt) 2020-02-11
SA116370660B1 (ar) 2019-02-24
CU20160055A7 (es) 2016-10-28
IL265381A (en) 2019-05-30
CA2923063A1 (fr) 2015-05-07
KR102174942B1 (ko) 2020-11-06
EP3542791A1 (fr) 2019-09-25
PH12016500307B1 (en) 2016-05-16
US10799515B2 (en) 2020-10-13
IL265381B (en) 2022-05-01
CN110279669A (zh) 2019-09-27
AU2020201365B2 (en) 2021-09-16
BR112016004863B1 (pt) 2022-09-20
TW201944984A (zh) 2019-12-01
CN105555260B (zh) 2021-04-23
EP3062776A1 (fr) 2016-09-07
CA2923063C (fr) 2021-09-07
JP6273356B2 (ja) 2018-01-31
IL244260B (en) 2021-08-31
KR20200075041A (ko) 2020-06-25
CN110279669B (zh) 2022-02-15
CN105555260A (zh) 2016-05-04
CR20160192A (es) 2016-07-13
SG11201600501UA (en) 2016-02-26
TWI736031B (zh) 2021-08-11
EA201690596A1 (ru) 2016-08-31
TWI725458B (zh) 2021-04-21
TW201542243A (zh) 2015-11-16
NZ747731A (en) 2020-02-28
SA114360006B1 (ar) 2016-11-09
UA117260C2 (uk) 2018-07-10
KR102237356B1 (ko) 2021-04-08
AU2013404367B2 (en) 2020-02-27
NZ717159A (en) 2019-06-28
EA032504B1 (ru) 2019-06-28
ZA201600630B (en) 2017-05-31
TN2016000119A1 (en) 2017-10-06
PH12016500307A1 (en) 2016-05-16

Similar Documents

Publication Publication Date Title
MA38847B2 (fr) Formulation médicamenteuse à libération retardée
JOP20200146B1 (ar) تركيبة عقار ذو إطلاق متأخر
WO2014184662A3 (fr) Formes posologiques solides à libération prolongée d'antiémétiques
RU2015140119A (ru) Таблетка, покрытая кишечнорастворимым покрытием
PH12018500304A1 (en) A delyade release drug formulation
JOP20210135A1 (ar) صيغة توصيل عقار قولوني
TH147933A (th) สูตรผสมยาชนิดปลดปล่อยแบบชะลอ
TH181888A (th) สูตรผสมยาชนิดปลดปล่อยแบบชะลอ
MX2019002162A (es) Formulacion de farmaco de liberacion retardada.
CU24302B1 (es) Formulación de fármaco de liberación retardada